However, despite several efforts to assess the efficacy of combining ICI with EGFR TKIs, the role of PD-L1 in EGFR mutant NSCLC and whether EGFR TKI treated NSCLC patients could benefit from combinational or subsequent immunotherapy is still controversial16. This evidence concerns the gene CD274 and non-small cell lung carcinoma.